Evidence map›Paper›PMID 42122169›Full record

ArticleCancers2026

An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and Identifies

Zhinan Xia, Yu Dong, Xin Zhang, Wenjiao Xia, Hongru Wang, Yiyang Zhou, Yiming Qi, Yulan Liang, Zhijian Li, Yuhang Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhinan XiaDepartment of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Yu DongDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Xin ZhangDepartment of Radiology, Second Affiliated Hospital of Naval Medical University, Shanghai 200000, China.
Wenjiao XiaDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Hongru WangDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Yiyang ZhouDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Yiming QiDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Yulan LiangDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Zhijian LiDepartment of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Yuhang ZhangDepartment of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Zhiming CuiDepartment of Radiology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Keliang WangDepartment of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Cheng ZhangDepartment of Urology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.ORCID 0000-0003-3758-5172

Funding

Zhejiang Provincial Natural Science Foundation LTGY24H160020Zhejiang Provincial Natural Science Foundation LZ22H160008
6 · The paper itself

Abstract

BACKGROUND/

objectivesClear cell renal cell carcinoma (ccRCC) involves complex interactions between immune evasion and metabolic reprogramming. This study aimed to characterize ccRCC through integrated immunometabolic profiling, develop a prognostic signature, and investigate the functional role of the key driver gene UCN using in vitro and in vivo approaches.

methodsIntegrated immunometabolic profiling was performed to identify molecular subtypes and establish a prognostic gene signature. Two distinct molecular subtypes were identified, and a 9-gene Immune Metabolic Index (IMI) was constructed. The functional role of the key driver gene UCN was investigated through in vitro functional assays and in vivo xenograft models in BALB/c mice, including combination with PD-1 blockade.

resultsTwo molecular subtypes with significant survival differences (

conclusionsThe IMI is a robust tool for risk stratification in ccRCC. Targeting the UCN-driven immunometabolic axis represents a promising therapeutic strategy to overcome immune resistance in ccRCC.

Indexed as

clear cell renal cell carcinomaimmune microenvironmentimmunometabolismimmunotherapymolecular subtypeUCN

Identifiers

PMID42122169
PMCPMC13163016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.